Expert opinion on the treatment of patients with chronic hepatitis C - sprookjes - yvandenbroek - TriplyDB

Expert opinion on the treatment of patients with chronic hepatitis C

Expert opinion on the treatment of patients with chronic hepatitis C

http://www.wikidata.org/entity/Q27489903

about

Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein What Are the Prospects for Controlling Hepatitis C?Towards a small animal model for hepatitis C Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C Individualisation of antiviral therapy for chronic hepatitis C.Interleukin-28B polymorphisms and response of chronic hepatitis C patients from Indonesia to pegylated interferon/ribavirin treatment Possible factors affecting thyroid dysfunction in hepatitis C virus-infected untreated patients Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin.Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins Elevated interferon-stimulated gene transcription in peripheral blood mononuclear cells occurs in patients infected with genotype 1 but not genotype 3 hepatitis C virus.Transcriptional Dysregulation of Upstream Signaling of IFN Pathway in Chronic HCV Type 4 Induced Liver Fibrosis.Amino Acid Polymorphisms in Hepatitis C Virus Core Affect Infectious Virus Production and Major Histocompatibility Complex Class I Molecule Expression.An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients A lower serum gamma-glutamyltransferase level does not predict a sustained virological response in patients with chronic hepatitis C genotype 1.Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection.Hepatitis C virus genotypes in north eastern Algeria: A retrospective study Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection.Development of murine models to study Hepatitis C virus induced liver pathogenesis.The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, India Genetic variants in interferon-λ 4 influences HCV clearance in Chinese Han population.Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches.Safety of small molecules in combination with interferon-based therapy for hepatitis C virus.Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.Hepatitis C virus RNA assays: current and emerging technologies and their clinical applications.Impact of HCV genetic differences on pathobiology of disease.Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs.Genetics of IL28B and HCV--response to infection and treatment.New therapeutic strategies in HCV: polymerase inhibitors.Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C.Treatment of chronic viral hepatitis C in children and adolescents: UK experience.

P2860

Q27014831-91ADEBAB-EAAA-4ECF-A085-43B07C9FC29E Q27333881-94128807-B1A3-4EA5-B546-5E1491FAF500 Q27488436-B8C5ED04-F147-48B6-A405-0952FCC017C6 Q27490373-93896E0F-89A8-4FF3-B056-AF21B14A5054 Q29417108-02ACAD64-D067-45CE-BC08-50FD08C5CBB1 Q31153267-9BF9EE82-9CB4-4886-B5BA-936B75D70B23 Q33390478-238D8EA6-517D-4975-8591-A4DA6DAD5518 Q33703323-6654E02E-A961-46BE-96CF-6EB95875CC15 Q33769658-1162E661-E991-4F9E-9359-A908A991A62E Q34008754-F5417754-F14D-4F0C-987D-11AF82BAB27E Q34058093-4F4DE763-3D29-446A-A707-5CA2B88E7FE5 Q34341819-B0D1FEE2-1873-462B-B1DE-3803C1CE92D2 Q34348799-B41F26D4-00AC-4747-8CD5-AA9820B69543 Q34741602-81D452FA-ABC3-48AC-A025-252163BD5454 Q34796179-297E6C8A-2401-436F-921F-FB4F3C97D29F Q35535783-C7FADCE7-083E-462B-9341-BEBAC7421A32 Q36004897-12BCBCD2-D724-4D1C-8163-367147AB5795 Q36056232-D45C8E1B-4F61-4ACE-BFD7-42CB77267110 Q36080110-32FDA41B-B425-455B-819E-579411899462 Q36541206-DA5ECA53-48B5-4D4A-97DF-024DB2F6696A Q36609569-62C30EE2-9A58-45ED-BA67-F391913DB369 Q36667165-04239549-7A8E-4EB9-8857-154FC08BE0A4 Q36907926-0657B887-276E-4793-B160-604E3E6BAA3E Q36963985-50BF14B8-DF64-4D03-A031-30C008289B01 Q37049123-82775CAE-3EF0-4D5D-85FB-3CFB180FBB6F Q37105208-B7ED2B6D-7E9E-4F19-A896-26C6E7221069 Q37201746-D314F014-3C3C-455F-B4E3-4E75074FE734 Q37613384-EA971075-6153-497E-9189-E56991E938E4 Q37635067-10E7C69E-46F3-4C0C-B18E-DB1BC02ADB8E Q37688134-702BFAA8-1211-4B3B-B57D-FB8BB79E754D Q37765571-77B38CBC-DAEE-4193-B56D-9F58FA6C3BC7 Q37818336-6D85C39D-9E8B-4E82-AFB8-A281C8D077FF Q37822462-5BB0C35E-9277-419E-8102-467D7F088E4B Q37929753-D7DCCEB1-764F-4C90-9391-6682BF63C2C7 Q37975253-E95F8F2B-7499-4CF7-83FB-0887A7345A48 Q37998132-49153382-E43B-4DD2-A03F-D47F7517317E Q38013941-3241DC6A-0F13-4B24-8BA4-1DEE9814BEF1 Q38071392-FA98323B-FEC5-46F3-B07D-CE0926D0F2A2 Q38076757-839A7ECC-A547-4249-BECB-6E763CB11FBB Q38184887-B0EA3D64-053D-45E0-9C0F-9A541FDC2464

P2860

Expert opinion on the treatment of patients with chronic hepatitis C

http://www.wikidata.org/entity/Q27489903

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Expert opinion on the treatment of patients with chronic hepatitis C

@ast

Expert opinion on the treatment of patients with chronic hepatitis C

@en

Expert opinion on the treatment of patients with chronic hepatitis C

@nl

type

label

Expert opinion on the treatment of patients with chronic hepatitis C

@ast

Expert opinion on the treatment of patients with chronic hepatitis C

@en

Expert opinion on the treatment of patients with chronic hepatitis C

@nl

prefLabel

Expert opinion on the treatment of patients with chronic hepatitis C

@ast

Expert opinion on the treatment of patients with chronic hepatitis C

@en

Expert opinion on the treatment of patients with chronic hepatitis C

@nl

P1433

Q27489903-4EAB4009-58F2-4337-B0C0-37D379AE6742

P1476

Q27489903-3824EFA9-3D40-4425-800B-68FCA35581CF

P2093

Q27489903-1A4D0A04-8E0F-4E0B-8EB8-B72B156295BF

Q27489903-2FDDA0E7-B0B7-4C71-93D3-E34A62FF8201

Q27489903-391BE100-DCBA-46CC-900F-8629BA1E3352

Q27489903-4659FF10-8665-4D39-823C-44582871B491

Q27489903-84B40992-1A5B-4A98-887B-AD1AC40B8BD6

Q27489903-A97FD69D-72A1-4DF8-82D5-68EC1FCFDE75

Q27489903-AE3D4F08-790B-4FEE-9099-3D4AE6AAC9B0

Q27489903-CB4DB975-E295-4472-AED2-B550949FFF64

Q27489903-E96C98A2-E70E-4C72-B6C9-CFAB84B8DAF3

P275

Q27489903-CE2A4F95-9453-42BE-BF65-1390698EBF9A

P2860

Q27489903-198E40CD-162C-4BFF-9883-EFBC7688F67C

Q27489903-1B9E8A43-2167-4D7A-83EC-30973FB006C7

Q27489903-1D5FD4FE-3397-4A48-BE88-E71B0EB302FE

Q27489903-1F16FB33-579C-4BEB-9C29-E6364E008E94

Q27489903-29998943-5FC3-41CF-B7D8-00992F7B3CD8

Q27489903-343916A5-7B19-4EA1-9A83-15B8D39CD405

Q27489903-3465626F-6439-4217-A769-3339F953DF0C

Q27489903-35A78DB7-4C2E-40AB-B3DF-658F86AB0938

Q27489903-36ED40E4-3693-4080-99CE-3D63BAA07DBB

Q27489903-37FDAF11-2E74-42E0-B994-5DE0A173B6FD

P304

Q27489903-8653235F-A7CB-4E83-A0EE-18337AB30DB3

P31

Q27489903-551263cd-af03-4915-92ed-ffa67fd0556f

Q27489903-94961F84-628C-4B54-919E-62F9F094E6FB

Q27489903-BE6C5856-CDD0-424F-8817-BAA862175B72

P3181

Q27489903-8A84C6A5-2061-460C-99FA-342C15740645

P356

Q27489903-75C0493B-71D8-4E6F-B91F-FC2A0E9DB41F

P433

Q27489903-079CA8B9-C629-45E4-BDAC-9899133B92EA

P478

Q27489903-26598B80-AB4F-4A37-AB8E-61EE1DDA8DEA

P50

Q27489903-81D8ADBC-9729-43DF-928B-9E39F7397729

P577

Q27489903-A0583C46-5ADF-4083-A834-C3723AD14228

P5875

Q27489903-44E960A3-B4B8-4550-A49D-86DAED4BEC84

P698

Q27489903-2BEDB71D-92F7-43D6-B96B-FA1E1B2BFB1C

P921

Q27489903-2623BFA0-1F01-4F3B-8F0E-0957E1D1BAA6

Q27489903-648C7ABA-EEA6-4C26-910A-92EB89B8ED30

Q27489903-A0A2F9B0-11AE-4D33-BF63-5E6885EE99BD

Q27489903-A63DD6BF-EB88-49BC-B9B2-920E5A773B9F

Q27489903-CF334D23-EE8F-403E-88D2-C08DBB6DF388

Q27489903-EED80629-7ACB-4290-9620-C65697741686

P932

Q27489903-C1F1455A-3907-4A1D-A86B-31B15AE09B06

P3181

P356

J.1365-2893.2008.01012.X

P1433

Journal of Viral Hepatitis

P1476

Expert opinion on the treatment of patients with chronic hepatitis C

@en

P2093

B Moeller

http://www.w3.org/2001/XMLSchema#string

C Sarrazin

http://www.w3.org/2001/XMLSchema#string

D Hueppe

http://www.w3.org/2001/XMLSchema#string

E Zehnter

http://www.w3.org/2001/XMLSchema#string

H Hinrichsen

http://www.w3.org/2001/XMLSchema#string

H Wedemeyer

http://www.w3.org/2001/XMLSchema#string

M P Manns

http://www.w3.org/2001/XMLSchema#string

S Mauss

http://www.w3.org/2001/XMLSchema#string

S Zeuzem

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Diagnosis, management, and treatment of hepatitis C

Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP).

Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

P304

75-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4517035

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/J.1365-2893.2008.01012.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23227910

http://www.w3.org/2001/XMLSchema#string

P698

18761607

http://www.w3.org/2001/XMLSchema#string

P921

manufactured product

macromolecular substances

P932

2759987

http://www.w3.org/2001/XMLSchema#string